Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned an average rating of “Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $49.91.

A number of research firms have recently weighed in on DYN. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research report on Friday, January 10th.

Insider Activity

In other news, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the sale, the senior vice president now owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. Insiders have sold a total of 21,071 shares of company stock valued at $606,476 in the last 90 days. 20.77% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its stake in shares of Dyne Therapeutics by 4.3% in the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after purchasing an additional 352 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Dyne Therapeutics by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares during the period. KBC Group NV raised its stake in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after acquiring an additional 751 shares during the period. Amalgamated Bank raised its stake in Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Dyne Therapeutics during the 3rd quarter worth approximately $34,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 1.5 %

Shares of NASDAQ DYN opened at $13.46 on Friday. Dyne Therapeutics has a 12 month low of $13.23 and a 12 month high of $47.45. The firm has a market capitalization of $1.37 billion, a PE ratio of -3.78 and a beta of 1.16. The firm has a fifty day simple moving average of $23.39 and a two-hundred day simple moving average of $32.15.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, sell-side analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.